SELPERCATINIB, SELPERCATINIB
LOXO-RET-18037
Approved small_molecule active
Quick answer
SELPERCATINIB, SELPERCATINIB for Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration; is a Approved program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;
- Phase
- Approved
- Modality
- small_molecule
- Status
- active